Connect with us
DAPA Banner

Business

Pfizer (PFE) earnings Q1 2026

Published

on

Pfizer (PFE) earnings Q1 2026

Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City.

View Press | Corbis News | Getty Images

Pfizer on Tuesday posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as its recently launched and acquired products showed growth.

Advertisement

Older top-selling drugs, including its blood thinner Eliquis, also helped drive demand in the quarter and offset the decline in revenue from Pfizer’s Covid vaccine and antiviral pill to treat the virus, Paxlovid.

Here’s what the company reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: 75 cents adjusted vs. 72 cents expected
  • Revenue: $14.45 billion vs. $13.79 billion expected

The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs. Pfizer is focused on several crucial data releases this year, including late-stage trial results on an experimental targeted drug in lung cancer. 

Pfizer reported revenue of $14.45 billion for the first quarter, up 5% from the same period a year ago. Sales increases for key products helped to counteract struggles in its Covid business.

The company booked net income of $2.69 billion, or 47 cents per share. That compares with net income of $2.97 billion, or 52 cents per share, during the same period a year ago.

Advertisement

Excluding certain items, including restructuring charges and costs associated with intangible assets, Pfizer posted earnings per share of 75 cents for the quarter.

Pfizer reaffirmed its 2026 outlook, expecting full-year adjusted profit to come in between $2.80 and $3 per share, and revenue to total $59.5 billion to $62.5 billion. That sales range would be roughly flat or down slightly compared with 2025 revenue of $62.6 billion.

Pfizer previously said the lackluster revenue outlook comes in part from declining sales of its Covid vaccine and Paxlovid, which it expects to fall by about $1.5 billion year over year to $5 billion. 

The company also pointed to another roughly $1.5 billion year-over-year expected drop in sales due to certain products losing their market exclusivity. Some blockbuster drugs, such as the company’s pneumonia vaccine Prevnar, are facing more competition from rivals.

Advertisement

The results come a week after Pfizer entered into settlement agreements with three generic drug manufacturers that effectively extend the company’s U.S. patent protection for Vyndamax until June 1, 2031. That’s a prescription medicine that helps treat a rare, serious heart condition.

Newer and older products offset Covid decline

Sales of Pfizer’s Covid shot and Paxlovid both came in well under analysts’ estimates, according to StreetAccount.

The vaccine raked in $232 million in revenue for the quarter, down 59% from the same period a year ago, while Paxlovid sales fell 62% to $186 million. Analysts were expecting sales of $445.9 million and $286.2 million, respectively, for the two products.

Meanwhile, Eliquis generated $2.17 billion in sales for the quarter, up 13% from the year-ago period. Analysts expected $1.96 billion in revenue, according to StreetAccount estimates. 

Advertisement

Other older drugs and some newer products also beat estimates for the quarter. 

Targeted cancer drug Padcev booked $591 million in revenue, up 39% from the same period a year ago and surpassing the $542.3 million that analysts were expecting. 

Pfizer’s vaccine against respiratory syncytial virus, a more recently launched product, booked $180 million in sales for the first quarter. That’s up 37% from the year-earlier period and comes in higher than the $145.1 million that analysts were expecting. 

Sales of recently launched and acquired products grew 22% operationally during the quarter, Pfizer said.

Advertisement
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Banco BPM S.p.A. 2026 Q1 – Results – Earnings Call Presentation (OTCMKTS:BNCZF) 2026-05-05

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Business

Strait of Hormuz tensions rise as Iran accused of ceasefire violations

Published

on

Strait of Hormuz tensions rise as Iran accused of ceasefire violations

The prospect of renewed conflict in the Middle East is intensifying as tensions escalate in the Strait of Hormuz, with military leaders warning that a return to sustained combat operations may be unavoidable following reported ceasefire violations by Iran.

TREASURY FREEZES $344M IN CRYPTO AS ‘OPERATION ECONOMIC FURY’ PUSHES IRAN TO INDUSTRIAL BREAKING POINT

Advertisement

Fox News senior strategic analyst, retired Gen. Jack Keane, joined FOX Business’ Cheryl Casone on “Mornings with Maria” to discuss the growing risks of escalation, as U.S. forces work to maintain open shipping lanes and protect commercial vessels in one of the world’s most critical energy passageways.

U.S. Navy in transit

U.S. Navy in transit in the Strait of Hormuz. (Zachary Pearson/U.S. Navy)

Keane pointed to recent Iranian actions, including reported attacks on U.S. and allied assets, as a turning point that could push the situation back into active conflict. Those developments come as the U.S. continues a large-scale operation to secure the Strait of Hormuz.

“There are two things that will likely force us to go back into combat operations… Fire on U.S. warships, that has happened, and also fire on our allies and partners in the region… That has happened as well,” Keane said.

Advertisement

TECH PRICES COULD RISE AS IRAN CONFLICT DISRUPTS ELECTRONICS SUPPLY CHAIN

The retired general emphasized that the current U.S. posture remains defensive, focused on ensuring safe passage for vessels while countering incoming threats ranging from drones to fast boats. At the same time, he underscored that Iran, not the U.S., initiated the latest round of hostilities.

“It is Iran who broke the ceasefire by firing at the ships… firing at U.S. warships… they violated the ceasefire, and we’re completely justified in responding to that,” Keane said.

Advertisement

LARRY KUDLOW: MORE BOMBING IS COMING AS IRAN PULLS OUT A BLANK PIECE OF PAPER TO TAKE TRUMPIAN DICTATION

Looking ahead, Keane warned that broader military engagement could soon follow.

“It’s inevitable that we’re going to return to combat operations here,” he said.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Advertisement
Continue Reading

Business

Harley-Davidson Q1 2026 slides: retail sales surge amid margin pressure

Published

on

Harley-Davidson Q1 2026 slides: retail sales surge amid margin pressure


Harley-Davidson Q1 2026 slides: retail sales surge amid margin pressure

Continue Reading

Business

Getting the ‘balanced dairy’ category off the ground

Published

on

Getting the ‘balanced dairy’ category off the ground

Consumers in the United States remain reluctant to embrace products that combine animal and plant-based proteins. 

Continue Reading

Business

Sourdough pizza restaurant Franco Manca confirms 16 branches to close

Published

on

Business Live

The brand’s parent firm has agreed to shut the sites as part of a company voluntary arrangement process

A Franco Manca restaurant

A Franco Manca restaurant(Image: Cambridge News)

Restaurant chain Franco Manca will push ahead with the closure of 16 venues after a restructuring plan was approved by creditors. Last month, parent firm The Fulham Shore said it planned to shut the sites as part of a company voluntary arrangement (CVA) process, which will also hit around 225 jobs.

Advertisement

The pizza brand currently runs 70 restaurants prior to the closures but said it has been knocked by “disproportionately high” UK taxes and a lack of business rates relief for restaurants. The effected restaurants were “no longer sustainable” as a result.

Franco Manca’s CVA proposal received back from more than 90 per cent of voting creditors, allowing it to get the go ahead.

Last week, Fulham Shore placed its sister restaurant brand The Real Greek into administration. It was immediately snapped up by Cote owner Karali Group but announced the close of nine of its 28 restaurants.

Marcel Khan, chief executive of Fulham Shore, said: “We are grateful for the support shown by our creditors today. Franco Manca is a fantastic brand with a strong heritage and loyal customer base.

Advertisement

“With this agreement in place, we will put the business back on a firm footing and press ahead with strengthening our customer offer and performance.”

Paul Berkovi, managing director of Alvarez & Marsal, said: “Today’s vote saw a significant majority of the company’s creditors support the CVA, reflecting constructive engagement across stakeholders.

“Against a challenging backdrop for the sector, this is an important step for Franco Manca, enabling the business to complete its financial restructuring and secure the platform for its operational transformation.”

Full list of Franco Manca branches to close

Battersea

Advertisement

Bishops Stortford

Brixton

Broadway Market

Bromley

Advertisement

Cheltenham

Chiswick

Didsbury

Glasgow

Advertisement

Hove

Kilburn

Lincoln

New Oxford Street

Advertisement

Plymouth

Stoke Newington

Tottenham Court Road

Advertisement
Continue Reading

Business

Investment fueling continued expansion for Smearcase

Published

on

Investment fueling continued expansion for Smearcase

Investment scaling startup’s expansion into 1,000 plus retailers.

Continue Reading

Business

Nissan to close UK line and cut 900 European jobs

Published

on

Nissan to close UK line and cut 900 European jobs

Nissan says it is considering working with a third party to fully utilise its Sunderland plant.

Continue Reading

Business

Tropicana adds electrolytes

Published

on

Tropicana adds electrolytes

Tropicana Hydrate is offered in two flavors. 

Continue Reading

Business

FDA Commissioner Marty Makary defends Replimune drug approval decision

Published

on

FDA Commissioner Marty Makary defends Replimune drug approval decision

Martin Makary, commissioner of the Food and Drug Administration, during a news conference at FDA headquarters in Silver Spring, Maryland, April 28, 2026.

Valerie Plesch | Bloomberg | Getty Images

U.S. Food and Drug Administration Commissioner Marty Makary defended himself in a CNBC interview aired Tuesday after months of pressure over recent drug rejections

Advertisement

The relentless heat reached a new fever pitch this week with a report from Bloomberg News detailing “paranoia, turmoil and backlash” at the agency under Makary’s tenure. An opinion piece from The Wall Street Journal asked if any administration official has created more headaches for President Donald Trump than Makary. The editorial specifically cited the FDA’s controversial rejection of a drug candidate for melanoma from Replimune

“I think that article in The Wall Street Journal is the ninth article they’ve posted in that opinion section, begging for Replimune’s approval,” Makary said in an interview with CNBC’s David Faber. “I don’t work for Replimune, I work for the American people, and I stand by the scientists at the FDA.”

Makary said three independent teams have arrived at the same conclusion, adding that the FDA has not made “corrupt sweetheart deals.” Replimune representatives have said the FDA has unfairly treated the company. 

Makary said he stands behind his review teams and that FDA commissioners overruling agency scientists has been a “disaster” every time it has happened. He cited examples like the FDA’s approval of an Alzheimer’s disease drug called Aduhelm and its clearance of a Covid-19 vaccine booster for young, healthy kids. 

Advertisement
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

Louisiana-Pacific shareholders elect directors and approve proposals at annual meeting

Published

on


Louisiana-Pacific shareholders elect directors and approve proposals at annual meeting

Continue Reading

Trending

Copyright © 2025